Tourmaline Bio (TRML) Competitors $15.81 -0.18 (-1.11%) As of 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRML vs. TARS, BEAM, CNTA, ARQT, ADPT, IMCR, SPRY, EWTX, SDGR, and BHVNShould you be buying Tourmaline Bio stock or one of its competitors? The main competitors of Tourmaline Bio include Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), Arcutis Biotherapeutics (ARQT), Adaptive Biotechnologies (ADPT), Immunocore (IMCR), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Schrodinger (SDGR), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Tourmaline Bio vs. Its Competitors Tarsus Pharmaceuticals Beam Therapeutics Centessa Pharmaceuticals Arcutis Biotherapeutics Adaptive Biotechnologies Immunocore ARS Pharmaceuticals Edgewise Therapeutics Schrodinger Biohaven Tarsus Pharmaceuticals (NASDAQ:TARS) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership. Which has more volatility and risk, TARS or TRML? Tarsus Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Which has higher earnings and valuation, TARS or TRML? Tourmaline Bio has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M9.17-$115.55M-$2.73-14.64Tourmaline BioN/AN/A-$73.21M-$3.21-4.93 Do insiders and institutionals have more ownership in TARS or TRML? 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 13.0% of Tourmaline Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor TARS or TRML? In the previous week, Tourmaline Bio had 2 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 4 mentions for Tourmaline Bio and 2 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.88 beat Tourmaline Bio's score of 0.71 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tourmaline Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is TARS or TRML more profitable? Tourmaline Bio has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Tourmaline Bio's return on equity of -26.75% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-44.91% -39.72% -25.74% Tourmaline Bio N/A -26.75%-26.11% Do analysts recommend TARS or TRML? Tarsus Pharmaceuticals presently has a consensus price target of $66.67, indicating a potential upside of 66.85%. Tourmaline Bio has a consensus price target of $49.33, indicating a potential upside of 212.00%. Given Tourmaline Bio's higher possible upside, analysts clearly believe Tourmaline Bio is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryTourmaline Bio beats Tarsus Pharmaceuticals on 10 of the 15 factors compared between the two stocks. Get Tourmaline Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TRML and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRML and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRML vs. The Competition Export to ExcelMetricTourmaline BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$405.49M$2.42B$5.52B$8.87BDividend YieldN/A1.80%5.36%4.13%P/E Ratio-4.929.1126.4319.81Price / SalesN/A644.17409.77110.94Price / CashN/A21.1625.8827.49Price / Book1.354.487.945.38Net Income-$73.21M$31.16M$3.15B$248.34M7 Day Performance-6.66%1.06%1.15%1.43%1 Month Performance-5.94%10.86%5.48%5.61%1 Year Performance24.11%1.82%33.02%18.27% Tourmaline Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRMLTourmaline Bio2.6903 of 5 stars$15.81-1.1%$49.33+212.0%+24.3%$405.49MN/A-4.9244TARSTarsus Pharmaceuticals2.2744 of 5 stars$40.60-0.1%$66.67+64.2%+49.0%$1.71B$182.95M-14.8750Positive NewsBEAMBeam Therapeutics2.3277 of 5 stars$16.71-0.3%$48.75+191.7%-27.4%$1.69B$63.52M-3.62510CNTACentessa Pharmaceuticals3.1036 of 5 stars$13.00+4.6%$27.89+114.5%+45.5%$1.66B$6.85M-7.18200ARQTArcutis Biotherapeutics2.1896 of 5 stars$14.40+4.2%$18.80+30.6%+50.8%$1.65B$212.82M-13.85150Positive NewsADPTAdaptive Biotechnologies3.3025 of 5 stars$10.56+1.7%$10.57+0.1%+221.8%$1.58B$178.96M-11.00790Gap DownIMCRImmunocore2.453 of 5 stars$31.12-0.7%$58.89+89.2%-7.4%$1.57B$310.20M-72.37320SPRYARS Pharmaceuticals3.0942 of 5 stars$16.57+4.9%$31.00+87.1%+105.1%$1.55B$89.15M-103.5690Positive NewsAnalyst UpgradeEWTXEdgewise Therapeutics3.47 of 5 stars$14.18-0.8%$39.78+180.5%-27.2%$1.50BN/A-9.1560News CoverageAnalyst ForecastSDGRSchrodinger2.6161 of 5 stars$20.35-0.5%$32.80+61.2%+4.0%$1.50B$207.54M-7.74790BHVNBiohaven2.7829 of 5 stars$14.44-0.2%$58.46+305.0%-59.3%$1.48BN/A-1.54239 Related Companies and Tools Related Companies Tarsus Pharmaceuticals Alternatives Beam Therapeutics Alternatives Centessa Pharmaceuticals Alternatives Arcutis Biotherapeutics Alternatives Adaptive Biotechnologies Alternatives Immunocore Alternatives ARS Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Schrodinger Alternatives Biohaven Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRML) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tourmaline Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tourmaline Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
